Chapter 57 Thrombolytic therapy for acute stroke

Handbook of Clinical Neurology

Volumn 94, Issue , 2008, Pages 1155-1193

  Schellinger, Peter D ^a,b   Köhrmann, Martin ^a   Hacke, Werner ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66049111074     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(08)94057-4     Document Type: Review

References (222)

1. Abciximab Emergent Stroke Treatment Trial Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 36 (2005) 880-890
2. Abe T., Kazama M., Naito I., et al. Clinical effect of urokinase (60,000 units/day) on cerebral infarction-comparative study by means of multiple center double blind test. Blood-Vessel 12 (1981) 321-341
3. Albers G.W., Bates V.E., Clark W.M., et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
4. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
5. Albers G.W., Thijs V., Wechsler L., et al. Results of the diffusion-weighted imaging evaluation for understanding stroke evolution (DEFUSE) study. Stroke 37 (2006) 635-636
6. Alexandrov A.V., Molina C.A., Grotta J.C., et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 (2004) 2170-2178
7. American Academy of Emergency Medicine Work Group on Thrombolytic Therapy in Stroke (2002). http://www.aaem.org/positionstatements/thrombolytictherapy.shtml
8. American Heart Association. Heart disease and stroke statistics-update 2004.American Heart Association (2004), Dallas, TX
9. Arnold M., Nedeltchev K., Schroth G., et al. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry 75 (2004) 857-862
10. Astrup J., Siesjö B., and Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke 12 (1981) 723-725
11. Atarashi J., Ohtomo E., Araki G., et al. Clinical utility of urokinase in the treatment of acute stage cerebral thrombosis: multi-center double blind study in comparison with placebo. Clin Eval 13 (1985) 659-709
12. Baird A.E., Lovblad K.O., Dashe J.F., et al. Clinical correlations of diffusion and perfusion lesion volumes in acute ischemic stroke. Cerebrovasc Dis 10 (2000) 441-448
13. Barber P.A., Darby D.G., Desmond P.M., et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology 51 (1998) 418-426
14. Barber P.A., Demchuk A.M., Zhang J., et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 355 (2000) 1670-1674
15. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
16. Barber M., Langhorne P., and Stott D.J. Barriers to delivery of thrombolysis for acute stroke. Age Ageing 33 (2004) 94-95
17. Basser P.J., and Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111 (1996) 209-219
18. Bateman B.T., Schumacher H.C., Boden-Albala B., et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 37 (2006) 440-446
19. Belayev L., Saul I., Curbelo K., et al. Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model. Stroke 34 (2003) 2221-2227
20. Bernik M.B., and Oller E.P. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. JClin Invest 53 (1973) 823-834
21. Brandt T., von Kummer R., Muller Kuppers M., et al. Thrombolytic therapy of acute basilar artery occlusion: variables affecting recanalization and outcome. Stroke 27 (1996) 875-881
22. Brandt T., Knauth M., Wildermuth S., et al. CT angiography and Doppler sonography for emergency assessment in acute basilar artery ischemia. Stroke 30 (1999) 606-612
23. Brandt T., Steinke W., Thie A., et al. Posterior cerebral artery territory infarcts: clinical features, infarct topography, causes and outcome. Multicenter results and a review of the literature. Cerebrovasc Dis 10 (2000) 170-182
24. Branston N.M., Strong A.J., and Symon L. Extracellular potassium activity, evoked potential and tissue blood flow. Relationships during progressive ischaemia in baboon cerebral cortex. J Neurol Sci 32 (1977) 305-321
25. Buckley B.T., Wainwright A., Meagher T., et al. Audit of a policy of magnetic resonance imaging with diffusion-weighted imaging as first-line neuroimaging for in-patients with clinically suspected acute stroke. Clin Radiol 58 (2003) 234-237
26. Chalela J.A., Ezzeddine M., Latour L.L., et al. Reversal of perfusion and diffusion abnormalities after intravenous thrombolysis for a lacunar infarction. J Neuroimaging 13 (2003) 152-154
27. Chalela J.A., Latour L.L., Jeffries N., et al. Hemorrhage and early MRI evaluation from the emergency room (HEME-ER): a prospective, single center comparison of MRI to CT for the emergency diagnosis of intracranial hemorrhage in patients with suspected acute cerebrovascular disease. Stroke 34 (2003) 239-240
28. Chalela J.A., Kang D.W., Luby M., et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol 55 (2004) 105-112
29. Chiu D., Krieger D., Villar-Cordova C., et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29 (1998) 18-22
30. Cho A.H., Lee D.H., Kim J.S., et al. MRI-based thrombolysis in acute stroke patients with unclear onset time is safe and feasible. Stroke 37 (2006) 634
31. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282 (1999) 2019-2026
32. Clark W.M., Albers G.W., Madden K.P., et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 31 (2000) 811-816
33. Cornu C., Boutitie F., Candelise L., et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: the thrombolysis in acute stroke pooling project. Stroke 31 (2000) 1555-1560
34. Daffertshofer M., Gass A., Ringleb P., et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 36 (2005) 1441-1446
35. Davis S.M., and Donnan G.A. Echoplanar Imaging Thrombolysis Evaluation Trial: EPITHET. International Stroke Conference. Orlando, FL (2006)
36. Davis S., Fisher M., and Warach S. Magnetic Resonance Imaging in Stroke (2003), University Press, Cambridge
37. Del Zoppo G.J., and Hosomi N. Mechanisms of thrombolysis. In: Lyden P.D. (Ed). Thrombolytic Therapy for Acute Stroke (2005), Humana Press, Totowa, NJ 3-27
38. Del Zoppo G.J., Higashida R.T., Furlan A.J., et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 29 (1998) 4-11
39. Demchuk A.M., Hill M.D., Barber P.A., et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA stroke study. Stroke 36 (2005) 2110-2115
40. Derex L., Nighoghossian N., Hermier M., et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 17 (2004) 238-241
41. Doerfler A., Engelhorn T., von Kummer R., et al. Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats. Radiology 206 (1998) 211-217
42. Donnan G.A., Davis S.M., Chambers B.R., et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 276 (1996) 961-966
43. Dunn B., Davis L., Todd J., et al. Annual Meeting of the American Academy of Neurology. San Francisco, CA (2004)
44. Eckert B., Koch C., Thomalla G., et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke 36 (2005) 1160-1165
45. Engelter S.T., Reichhart M., Sekoranja L., et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 65 (2005) 1795-1798
46. Epple G., Schleuning W.D., Kettelgerdes G., et al. Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2. J Thromb Haemost 2 (2004) 962-968
47. European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 16 (2003) 311-337
48. Fagan S.C., Morgenstern L.B., Petitta A., et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50 (1998) 883-890
49. Fiebach J.B., and Schellinger P.D. Stroke MRI (2003), Steinkopff Verlag, Darmstadt
50. Fiebach J.B., Schellinger P.D., Jansen O., et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 33 (2002) 2206-2210
51. Fiebach J.B., Schellinger P.D., Gass A., et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 35 (2004) 502-507
52. Fiehler J., Foth M., Kucinski T., et al. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke 33 (2002) 79-86
53. Fiehler J., Boulanger J.M., Kakuda W., et al. Bleeding risk analysis in stroke by T2*-weighted imaging before thrombolysis (BRASIL): a multicenter study of 600 patients of the MR Stroke Collaborative Group. Stroke 37 (2006) 636
54. Fink J.N., Kumar S., Horkan C., et al. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke 33 (2002) 988-993
55. Fisher M., and Albers G.W. Applications of diffusion-perfusion magnetic resonance imaging in acute ischemic stroke. Neurology 52 (1999) 1750-1756
56. Furlan A., Higashida R., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282 (1999) 2003-2011
57. Garabedian H.D., Gold H.K., Leinbach R.C., et al. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 9 (1987) 599-607
58. Ginsberg M.D., and Pulsinelli W.A. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann Neurol 36 (1994) 553-554
59. Gonzales N.R., Albright K.C., Noser E.A., et al. "Mild stroke" should not exclude patients from thrombolytic therapy. Stroke 37 (2006) 621
60. Graham G.D. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 34 (2003) 2847-2850
61. Grond M., von Kummer R., Sobesky J., et al. Early computed-tomography abnormalities in acute stroke. Lancet 350 (1997) 1595-1596
62. Grond M., Rudolf J., Schmulling S., et al. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. Arch Neurol 55 (1998) 466-469
63. Grond M., Stenzel C., Schmulling S., et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29 (1998) 1544-1549
64. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
65. Hacke W., and Warach S. Diffusion-weighted MRI as an evolving standard of care in acute stroke. Neurology 54 (2000) 1548-1549
66. Hacke W., Zeumer H., Ferbert A., et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19 (1988) 1216-1222
67. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
68. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
69. Hacke W., Brott T., Caplan L., et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53 (1999) S3-S14
70. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
71. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
72. Haley Jr. E.C., Brott T.G., Sheppard G.L., et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 24 (1993) 1000-1004
73. Haley Jr. E.C., Lyden P.D., Johnston K.C., et al. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36 (2005) 607-612
74. Hamberg L.M., Hunter G.J., Halpern E.F., et al. Quantitative high-resolution measurement of cerebrovascular physiology with slip-ring CT. AJNR Am J Neuroradiol 17 (1996) 639-650
75. Handschu R., Garling A., Heuschmann P.U., et al. Acute stroke management in the local general hospital. Stroke 32 (2001) 866-870
76. Heiland S., Reith W., Forsting M., et al. Perfusion-weighted MRI using gadobutrol as a contrast agent in a rat stroke model. J Magn Reson Imaging 7 (1997) 1109-1115
77. Heuschmann P.U., Berger K., Misselwitz B., et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German stroke registers study group. Stroke 34 (2003) 1106-1113
78. Heuschmann P.U., Kolominsky-Rabas P.L., Roether J., et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 292 (2004) 1831-1838
79. Hill M.D., and Buchan A.M. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172 (2005) 1307-1312
80. Hjort N., Butcher K., Davis S.M., et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 36 (2005) 388-397
81. Hommel M., Boissel J.P., Cornu C., et al. Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group. Lancet 345 (1995) 57
82. Hossman K.A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 36 (1994) 557-565
83. Hu H.H., Teng M.M., Hsu L.C., et al. A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window. Stroke 37 (2006) 918-919
84. IMS Investigators. International Stroke Conference. Orlando, FL (2007)
85. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 35 (2004) 904-911
86. IMS Study Investigators. Hemorrhage in the interventional management of stroke study. Stroke 37 (2006) 847-851
87. Ingall T.J., O'Fallon W.M., Asplund K., et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 35 (2004) 2418-2424
88. IST3 Study Group. http://www.dcn.ed.ac.uk/ist3
89. Jackson A. Technical Progress in Neuroradiology and its Application. In: Demaerel P. (Ed). Recent Advances in Diagnostic Neuroradiology (2001), Springer-Verlag, Berlin 23-46
90. Jansen O., Schellinger P.D., Fiebach J.B., et al. Early recanalization in acute ischemic stroke saves tissue at risk defined by MRI. Lancet 353 (1999) 2036-2037
91. Junghans U., Seitz R.J., Wittsack H.J., et al. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases. Radiology 221 (2001) 795-801
92. Junghans U., Seitz R.J., Ritzl A., et al. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban. Neurology 58 (2002) 474-476
93. Kaste M. Approval of alteplase in Europe: will it change stroke management?. Lancet Neurol 2 (2003) 207-208
94. Kaste M. Thrombolysis: what more does it take?. Stroke 36 (2005) 200-202
95. Katzan I.L., Furlan A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
96. Kidwell C.S., Alger J.R., and Saver J.L. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34 (2003) 2729-2735
97. Kidwell C.S., Saver J.L., Mattiello J., et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 47 (2000) 462-469
98. Kidwell C.S., Saver J.L., Villablanca J.P., et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 33 (2002) 95-98
99. Kidwell C.S., Chalela J.A., Saver J.L., et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 292 (2004) 1823-1830
100. Knauth M., Kummer R.V., Jansen O., et al. Potential of CT angiography in acute ischemic stroke. AJNR Am J Neuroradiol 18 (1997) 1001-1010
101. Koenig M., Klotz E., Luka B., et al. Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. Radiology 209 (1998) 85-93
102. Koenig M., Banach-Planchamp R., Kraus M., et al. CT-Perfusionsbildgebung beim akuten ischämischen Hirn-infarkt: Vergleich von Parameterbildern der zerebralen Perfusion und Nativ-CT-Befunden. Fortschr Geb Rontgenstrahlen Neuen Bildgeb Verfahr Erganzungsbd 172 (2000) 219-226
103. Koenig M., Kraus M., Theek C., et al. Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived from perfusion CT. Stroke 32 (2001) 431-437
104. Krol A.L., Dzialowski I., Roy J., et al. Risk of contrast-induced nephropathy in acute stroke imaging. Stroke 37 (2006) 653-654
105. Kruithof E.K., and Schleuning W.D. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator. Thromb Haemost 92 (2004) 559-567
106. Kwiatkowski T.G., Libman R.B., Frankel M., et al. N Engl J Med 340 (1999) 1781-1787
107. Lansberg M.G., Thijs V.N., Bammer R., et al. Clinical and MRI-based risk factors for symptomatic intracerebral hemorrhage following treatment with tissue plasminogen activator. Stroke 37 (2006) 654
108. Larrue V., von Kummer R.R., Muller A., et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32 (2001) 438-441
109. Latour L.L., Kang D.W., Ezzeddine M.A., et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 56 (2004) 468-477
110. Lauterbur P. Image formation by induced local interactions: examples employing nuclear magnetic resonance. Nature 242 (1973) 190-191
111. Le Bihan D., Breton E., Lallemand D., et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161 (1986) 401-407
112. Le Bihan D., Turner R., Douek P., et al. Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 159 (1992) 591-599
113. Le Bihan D., Mangin J.F., Poupon C., et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 13 (2001) 534-546
114. Lees K.R., Zivin J.A., Ashwood T., et al. NXY-059 for acute ischemic stroke. N Engl J Med 354 (2006) 588-600
115. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ 324 (2002) 723-729
116. Lev M.H., Farkas J., Gemmete J.J., et al. Acute stroke: improved nonenhanced CT detection-benefits of soft-copy interpretation by using variable window width and center level settings. Radiology 213 (1999) 150-155
117. Levy D.E., Brott T.G., Haley Jr. E., et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 25 (1994) 291-297
118. Lewandowski C.A., Frankel M., Tomsick T.A., et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) bridging trial. Stroke 30 (1999) 2598-2605
119. Lijnen H.R., Van Hoef B., De Cock F., et al. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 73 (1989) 1864-1872
120. Lindsberg P.J., and Mattle H.P. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 37 (2006) 922-928
121. Lindsberg P.J., Soinne L., Tatlisumak T., et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 292 (2004) 1862-1866
122. Lovblad K.O., Baird A.E., Schlaug G., et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol 42 (1997) 164-170
123. Lyden P., Brott T., Tilley B., et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25 (1994) 2220-2226
124. Macleod M.R., Davis S.M., Mitchell P.J., et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 20 (2005) 12-17
125. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel index. Md Med J (1965) 21-23, 61-65
126. Mansfield P., and Maudsley A.A. Line scan proton spin imaging in biological structures by NMR. Phys Med Biol 21 (1976) 847-852
127. Mansfield P., and Maudsley A.A. Medical imaging by NMR. Br J Radiol 50 (1977) 188-194
128. Mar J., Begiristain J.M., and Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 20 (2005) 193-200
129. Marks M.P., Thijs V.N., Kakuda W., et al. Association of early recanalization with reperfusion and clinical outcome following intravenous tPA at 3 to 6 hours: results of the DEFUSE Study. Stroke 37 (2006) 635
130. Memezawa H., Minamisawa H., Smith M.L., et al. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res 89 (1992) 67-78
131. Meyer J.S., Gilroy J., Barnhart M.I., et al. Therapeutic thrombolysis in cerebral thrombo-embolism. Neurology 13 (1963) 927-937
132. Mitchell P.J., Gerraty R.P., Donnan G.A., et al. Thrombolysis in the vertebrobasilar circulation-the Australian Urokinase Stroke Trial (AUST) pilot study. Cerebrovasc Dis 7 (1997) 94-99
133. Mohr J.P., Biller J., Hilal S.K., et al. Magnetic resonance versus computed tomographic imaging in acute stroke. Stroke 26 (1995) 807-812
134. Molina C.A., Ribo M., Rubiera M., et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 37 (2006) 425-429
135. Mori E., Tabuchi M., Yoshida T., et al. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 19 (1988) 802-812
136. Mori E., Yoneda Y., Tabuchi M., et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42 (1992) 976-982
137. Morris A.D., Ritchie C., Grosset D.G., et al. A pilot study of streptokinase for acute cerebral infarction. QJM 88 (1995) 727-731
138. Moseley M.E., Wendland M.F., and Kucharczyk J. Magnetic resonance imaging of diffusion and perfusion. Top Magn Reson Imaging 3 (1991) 50-67
139. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 346 (1995) 1509-1514
140. Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335 (1996) 145-150
141. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
142. Neil J.J., Shiran S.I., McKinstry R.C., et al. Normal brain in human newborns: apparent diffusion coefficient and diffusion anisotropy measured by using diffusion tensor MR imaging. Radiology 209 (1998) 57-66
143. Neumann-Haefelin T., Wittsack H.J., Wenserski F., et al. Diffusion- and perfusion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 30 (1999) 1591-1597
144. Nighoghossian N., Hermier M., Adeleine P., et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study. Stroke 33 (2002) 735-742
145. Ohtomo E., Araki G., Itoh E., et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis: multi-centre double blind study. Clin Eval 15 (1985) 711-731
146. Ono J., Harada K., Takahashi M., et al. Differentiation between dysmyelination and demyelination using magnetic resonance diffusional anisotropy. Brain Res 671 (1995) 141-148
147. Ostergaard L., Weisskoff R.M., Chesler D.A., et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36 (1996) 715-725
148. Pancioli A. International Stroke Conference. Orlando, FL (2006). http://www.strokecenter.org/trials
149. Parsons M.W., Barber P.A., Chalk J., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 51 (2002) 28-37
150. Patel S.C., Levine S.R., Tilley B.C., et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 286 (2001) 2830-2838
151. Pexman J.H., Barber P.A., Hill M.D., et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 22 (2001) 1534-1542
152. Pierpaoli C., Jezzard P., Basser P.J., et al. Diffusion tensor MR imaging of the human brain. Radiology 201 (1996) 637-648
153. Potter van Loon B.J., Rijken D.C., Brommer E.J., et al. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67 (1992) 101-105
154. Powers W.J. Testing a test: a report card for DWI in acute stroke. Neurology 54 (2000) 1549-1551
155. Powers W.J., and Zivin J. Magnetic resonance imaging in acute stroke: not ready for prime time. Neurology 50 (1998) 842-843
156. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scott Med J 2 (1957) 200-215
157. Reed S.D., Cramer S.C., Blough D.K., et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32 (2001) 1832-1840
158. Rijken D.C., Hoylaerts M., and Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 257 (1982) 2920-2925
159. Rosen B.R., Belliveau J.W., and Chien D. Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 5 (1989) 263-281
160. Rosen B.R., Belliveau J.W., Vevea J.M., et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 14 (1990) 249-265
161. Röther J., Jonetz-Mentzel L., Fiala A., et al. Hemodynamic assessment of acute stroke using dynamic single-slice computed tomographic perfusion imaging. Arch Neurol 57 (2000) 1161-1166
162. Röther J., Schellinger P.D., Gass A., et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 33 (2002) 2438-2445
163. Rubiera M., Ribo M., Delgado-Mederos R., et al. Efficacy of microbubble-enhanced sonothrombolysis among stroke subtypes. Stroke 37 (2006) 621
164. Sacco R.L., Shi T., Zamanillo M.C., et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44 (1994) 626-634
165. Saver J.L., and Yafeh B. Robust confirmation of treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 37 (2006) 622
166. Schellinger P.D., and Fiebach J.B. Hypervolemia in aneurysmal subarachnoid hemorrhage. Stroke 36 (2005) 1104-1105
167. Schellinger P.D., Jansen O., Fiebach J.B., et al. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am J Neuroradiol 21 (2000) 1184-1189
168. Schellinger P.D., Fiebach J.B., Jansen O., et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 49 (2001) 460-469
169. Schellinger P.D., Fiebach J.B., Mohr A., et al. Thrombolytic therapy for ischemic stroke-a review. Part II-intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med 29 (2001) 1819-1825
170. Schellinger P.D., Fiebach J.B., Mohr A., et al. Thrombolytic therapy for ischemic stroke-a review. Part I-intravenous thrombolysis. Crit Care Med 29 (2001) 1812-1818
171. Schellinger P.D., Fiebach J.B., and Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 34 (2003) 575-583
172. Schlaug G., Benfield A., Baird A.E., et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 53 (1999) 1528-1537
173. Schmulling S., Grond M., Rudolf J., et al. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke 31 (2000) 1552-1554
174. Schonewille W.J., Algra A., Serena J., et al. Outcome in patients with basilar artery occlusion treated conventionally. J Neurol Neurosurg Psychiatry 76 (2005) 1238-1241
175. Schramm P., Schellinger P.D., Fiebach J.B., et al. Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke 33 (2002) 2426-2432
176. Schramm P., Schellinger P.D., Klotz E., et al. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. Stroke 35 (2004) 1652-1658
177. Seitz R.J., Hamzavi M., Junghans U., et al. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 34 (2003) 1932-1935
178. Shrier D.A., Tanaka H., Numaguchi Y., et al. CT angiography in the evaluation of acute stroke. AJNR Am J Neuroradiol 18 (1997) 1011-1020
179. Sobesky J., Weber O.Z., Lehnhardt F.G., et al. Which time-to-peak threshold best identifies penumbral flow?: a comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke. Stroke 35 (2004) 2843-2847
180. Sobesky J., Weber O.Z., Lehnhardt F.G., et al. Does the mismatch match the penumbra?: magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 36 (2005) 980-985
181. Sorensen A.G., Buonanno F.S., Gonzalez R.G., et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 199 (1996) 391-401
182. Steiner T., Bluhmki E., Kaste M., et al. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis 8 (1998) 198-203
183. Stejskal E.O., and Tanner J.E. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42 (1965) 288-292
184. Stewart R.J., Fredenburgh J.C., and Weitz J.I. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 273 (1998) 18292-18299
185. Tanne D., Bates V.E., Verro P., et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 53 (1999) 424-427
186. Tanner J.E., and Stejskal E.O. Restricted self-diffusion of protons in colloidal systems by the pulsed-gradient, spin-echo method. J Chem Phys 49 (1968) 1768-1777
187. Thall P.F., and Cook J.D. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60 (2004) 684-693
188. Thomalla G., Schwark C., Sobesky J., et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA Trials. Stroke 37 (2006) 852-858
189. Tillet W.S., and Garner R.L. The fibrinolytic activity of hemolytic streptococci. J Exp Med 58 (1933) 485-502
190. TIMI Study Group. The Thrombolysis in Myocardial Infarction trial: phase 1 findings. N Engl J Med 312 (1985) 932-936
191. Tognoni G., and Roncaglioni M.C. Dissent: an alternative interpretation of MAST-I. Multicentre Acute Stroke Trial-Italy Group. Lancet 346 (1995) 1515
192. Tong D.C., Yenari M.A., Albers G.W., et al. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology 50 (1998) 864-870
193. Tsushima Y., Aoki J., and Endo K. Brain microhemorrhages detected on T2*-weighted gradient-echo MR images. AJNR Am J Neuroradiol 24 (2003) 88-96
194. Villringer A., Rosen B.R., Belliveau J.W., et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 6 (1988) 164-174
195. Viswanathan A., and Chabriat H. Cerebral microhemorrhage. Stroke 37 (2006) 550-555
196. Von Kummer R. Effect of training in reading CT scans on patient selection for ECASS II. Neurology 51 (1998) S50-S52
197. Von Kummer R. Brain hemorrhage after thrombolysis: good or bad?. Stroke 33 (2002) 1446-1447
198. Von Kummer R. Imaging of stroke pathology without predefined gold standard. Cerebrovasc Dis 14 (2002) 270 Author Reply 271
199. Von Kummer R., Meyding-Lamade U., Forsting M., et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 15 (1994) 9-15
200. Von Kummer R., Bozzao L., and Manelfe C. Early CT Diagnosis of Hemispheric Brain Infarction (1995), Springer Verlag, Berlin
201. Von Kummer R., Nolte P.N., Schnittger H., et al. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke. Neuroradiology 38 (1996) 31-33
202. Von Kummer R., Allen K.L., Holle R., et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 205 (1997) 327-333
203. Wagner O.F., de Vries C., Hohmann C., et al. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest 84 (1989) 647-655
204. Warach S. Tissue viability thresholds in acute stroke: the 4-factor model. Stroke 32 (2001) 2460-2461
205. Warach S. Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med 2 (2001) 38-44
206. Warach S. Measurement of the ischemic penumbra with MRI: it's about time. Stroke 34 (2003) 2533-2534
207. Warach S., and Schellinger P.D. The role of stroke MRI in clinical trials. In: Fiebach J.B., and Schellinger P.D. (Eds). Stroke MRI (2003), Steinkopff Verlag, Darmstadt 91-99
208. Warach S., Chien D., Li W., et al. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 42 (1992) 1717-1723
209. Warach S., Dashe J.F., and Edelman R.R. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab 16 (1996) 53-59
210. Warach S., Boska M., and Welch K.M. Pitfalls and potential of clinical diffusion-weighted MR imaging in acute stroke. Stroke 28 (1997) 481-482
211. Wardlaw J.M., del Zoppo G., and Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2 (2002) CD000213
212. Warlow C.P. BMJ 324 (2002) 726-727
213. Wegener S., Gottschalk B., Jovanovic V., et al. Transient ischemic attacks before ischemic stroke: preconditioning the human brain?: a multicenter magnetic resonance imaging study. Stroke 35 (2004) 616-621
214. Weisskoff R.M., Chesler D., Boxerman J.L., et al. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: which mean transit time?. Magn Reson Med 29 (1993) 553-559
215. WHO Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999) 151-183
216. Wildermuth S., Knauth M., Brandt T., et al. Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke. Stroke 29 (1998) 935-938
217. Wintermark M., Michel P., Reichhart M., et al. Comparison of perfusion-CT/CT angiography and MRI in the selection of stroke patients for acute treatment. Stroke 37 (2006) 634
218. Yamaguchi T., Hayakawa T., Kiuchi H., and Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 3 (1993) 269-272
219. Zeumer H., Hacke W., Kolmann H.L., et al. [Local fibrinolysis in basilar artery thrombosis (author's transl.)]. Dtsch Med Wochenschr 107 (1982) 728-731
220. Zeumer H., Freitag H.J., Zanella F., et al. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 35 (1993) 159-162
221. Zivin J.A. Perfusion-weighted imaging/diffusion-weighted imaging mismatch on MRI can now be used to select patients for recombinant tissue plasminogen activator beyond 3 hours. Stroke 36 (2005) 1105-1106
222. Zivin J.A., and Holloway R.G. Weighing the evidence on DWI: caveat emptor. Neurology 54 (2000) 1552